TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.

Original reporting
Published Nov 5, 2026, 9:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CAI
Bearish
high confidence
Mentioned
$CAI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CAIBearishMed
01

Why it matters

The earnings miss triggered a 15% post‑close decline despite a higher price target, indicating short‑term weakness.

02

Market read

Earnings release with mixed signals; price target raise may not offset profit miss, leading to near‑term downside risk.

03

What to watch

Clinical volume growth and strong gross margins could support a turnaround if cost discipline improves.

Relevance 7/10Novelty 7/10Timing: after market close

Background

Caris Life Sciences reported Q3 results with 85% YoY revenue growth, a 9% sales beat, but earnings of $0.05 vs $0.16 expected.

Company-level read

Ticker impact

$CAIBearishHigh confidence
Context

TD Cowen raised its price target on Caris Life Sciences (CAI) to $38 after the company reported Q3 sales beat but missed profit expectations, causing a 15% post‑close decline.

Expected impact

downward pressure as investors price in the earnings miss and profit shortfall

Evidence & confidence

The stock fell 15% after hours; the profit miss outweighs the sales beat and target raise, likely prompting further short‑term selling.

Market effects

Highlights volatility in the biotech services sector where sales growth may not translate to earnings, prompting caution on peers.

U.S. biotech stocks may see modest pullback as investors reassess profit expectations.

Limited to biotech and healthcare investors; no broad market effect.

Counterpoint

The raised price target suggests upside potential if the company can convert sales growth into profitability.

Key entities

  • Caris Life Sciences Inc.

    U.S. biotech services firm (NASDAQ:CAI).

  • TD Cowen

    Equity research firm that raised CAI's price target.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

Caris Life Sciences Q3 Earnings Call Highlights

Caris Life Sciences reported Q3 net income of $15.3M, down from $24.3M YoY, with adjusted EBITDA at $44.4M. Operating expenses rose to $163M, and full-year expense forecast increased to $620M. Free cash flow was negative $39.7M. The company launched new cancer-detection tests and plans to introduce them selectively. Caris Detect, a multi-cancer early detection test, is being marketed with campaigns and partnerships. The company has 325 commercial team members and plans to expand further.